Financhill
Sell
22

BIVI Quote, Financials, Valuation and Earnings

Last price:
$1.04
Seasonality move :
70.38%
Day range:
$1.02 - $1.10
52-week range:
$0.62 - $7.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.79x
Volume:
520.5K
Avg. volume:
643.7K
1-year change:
-79.35%
Market cap:
$19M
Revenue:
--
EPS (TTM):
-$3.46

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIVI
BioVie
-- -$0.44 -- -41.86% $6.00
ACXP
Acurx Pharmaceuticals
-- -$0.12 -- -59.62% $5.70
AXSM
Axsome Therapeutics
$162.6M -$0.91 61.04% -35.15% $176.53
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
TNXP
Tonix Pharmaceuticals Holding
$2.7M -$3.09 17.75% -99.42% $60.00
TOVX
Theriva Biologics
-- -$0.43 -- -8.25% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIVI
BioVie
$1.03 $6.00 $19M -- $0.00 0% --
ACXP
Acurx Pharmaceuticals
$0.39 $5.70 $9.1M -- $0.00 0% --
AXSM
Axsome Therapeutics
$107.53 $176.53 $5.3B -- $0.00 0% 12.01x
NBY
NovaBay Pharmaceuticals
$0.59 $0.85 $3.4M -- $0.00 0% 0.16x
TNXP
Tonix Pharmaceuticals Holding
$28.00 $60.00 $205.1M -- $0.00 0% 7.65x
TOVX
Theriva Biologics
$0.56 $7.00 $1.6M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIVI
BioVie
-- -0.718 -- --
ACXP
Acurx Pharmaceuticals
-- 2.025 -- --
AXSM
Axsome Therapeutics
77.32% 1.593 3.16% 1.90x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
TNXP
Tonix Pharmaceuticals Holding
-- -9.056 -- 11.24x
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIVI
BioVie
-- -$7.3M -- -- -- -$8.6M
ACXP
Acurx Pharmaceuticals
-- -$2.1M -- -- -- -$2.1M
AXSM
Axsome Therapeutics
$111.7M -$55.5M -103.06% -309.19% -46.91% -$43.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
TNXP
Tonix Pharmaceuticals Holding
$1.5M -$15.1M -114.25% -121.16% -622.93% -$16.6M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

BioVie vs. Competitors

  • Which has Higher Returns BIVI or ACXP?

    Acurx Pharmaceuticals has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Acurx Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    ACXP
    Acurx Pharmaceuticals
    -- -$0.11 --
  • What do Analysts Say About BIVI or ACXP?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 482.52%. On the other hand Acurx Pharmaceuticals has an analysts' consensus of $5.70 which suggests that it could grow by 1372.22%. Given that Acurx Pharmaceuticals has higher upside potential than BioVie, analysts believe Acurx Pharmaceuticals is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    ACXP
    Acurx Pharmaceuticals
    1 0 0
  • Is BIVI or ACXP More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Acurx Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIVI or ACXP?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acurx Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Acurx Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or ACXP?

    BioVie quarterly revenues are --, which are smaller than Acurx Pharmaceuticals quarterly revenues of --. BioVie's net income of -$7.1M is lower than Acurx Pharmaceuticals's net income of -$2.1M. Notably, BioVie's price-to-earnings ratio is -- while Acurx Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for Acurx Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    ACXP
    Acurx Pharmaceuticals
    -- -- -- -$2.1M
  • Which has Higher Returns BIVI or AXSM?

    Axsome Therapeutics has a net margin of -- compared to BioVie's net margin of -48.92%. BioVie's return on equity of -- beat Axsome Therapeutics's return on equity of -309.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    AXSM
    Axsome Therapeutics
    91.94% -$1.22 $234.6M
  • What do Analysts Say About BIVI or AXSM?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 482.52%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.53 which suggests that it could grow by 64.17%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    AXSM
    Axsome Therapeutics
    13 0 0
  • Is BIVI or AXSM More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

  • Which is a Better Dividend Stock BIVI or AXSM?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or AXSM?

    BioVie quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. BioVie's net income of -$7.1M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, BioVie's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 12.01x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    AXSM
    Axsome Therapeutics
    12.01x -- $121.5M -$59.4M
  • Which has Higher Returns BIVI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to BioVie's net margin of -49.65%. BioVie's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About BIVI or NBY?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 482.52%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.07%. Given that BioVie has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioVie is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is BIVI or NBY More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock BIVI or NBY?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or NBY?

    BioVie quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioVie's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, BioVie's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns BIVI or TNXP?

    Tonix Pharmaceuticals Holding has a net margin of -- compared to BioVie's net margin of -692.84%. BioVie's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -121.16%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    TNXP
    Tonix Pharmaceuticals Holding
    61.18% -$2.84 $180.4M
  • What do Analysts Say About BIVI or TNXP?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 482.52%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 114.29%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    TNXP
    Tonix Pharmaceuticals Holding
    1 0 0
  • Is BIVI or TNXP More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.658%.

  • Which is a Better Dividend Stock BIVI or TNXP?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or TNXP?

    BioVie quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.4M. BioVie's net income of -$7.1M is higher than Tonix Pharmaceuticals Holding's net income of -$16.8M. Notably, BioVie's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 7.65x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    TNXP
    Tonix Pharmaceuticals Holding
    7.65x -- $2.4M -$16.8M
  • Which has Higher Returns BIVI or TOVX?

    Theriva Biologics has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About BIVI or TOVX?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 482.52%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1152.68%. Given that Theriva Biologics has higher upside potential than BioVie, analysts believe Theriva Biologics is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is BIVI or TOVX More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock BIVI or TOVX?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or TOVX?

    BioVie quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. BioVie's net income of -$7.1M is lower than Theriva Biologics's net income of -$4.4M. Notably, BioVie's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Newegg Commerce Up So Much?
Why Is Newegg Commerce Up So Much?

Consumer electronics eCommerce store Newegg (NASDAQ:NEGG) has staged a dramatic…

Is Unity Software a Buy Now?
Is Unity Software a Buy Now?

Unity Software (NYSE:U) is the company behind the popular Unity…

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 17

Semler Scientific [SMLR] is up 28.56% over the past day.

Sell
25
GLOB alert for May 17

Globant SA [GLOB] is down 23.54% over the past day.

Buy
94
HIMS alert for May 17

Hims & Hers Health [HIMS] is up 10.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock